# Clinical Cases: Antimicrobial Pharmacology

## Case 1: MRSA Bacteremia with Vancomycin Monitoring

### Clinical Scenario
A 58-year-old male with end-stage renal disease on hemodialysis presents with fever and rigors 2 days after his dialysis session.

### Patient Demographics
- **Age:** 58 years
- **Sex:** Male
- **Weight:** 85 kg
- **Dialysis schedule:** Monday, Wednesday, Friday

### Chief Complaint
Fever, chills, and feeling "terrible" for 24 hours

### History of Present Illness
The patient has ESRD on hemodialysis via a tunneled catheter placed 3 months ago. He developed fevers to 39.5C starting the day after his last dialysis session. He has had rigors, malaise, and decreased appetite. No localizing symptoms of infection. His catheter exit site appears unremarkable.

### Physical Examination
- **Vital Signs:** BP 100/65 mmHg, HR 108 bpm, RR 20, T 39.2C
- **General:** Ill-appearing, rigors during examination
- **HEENT:** No oral lesions, no neck stiffness
- **Cardiovascular:** Tachycardic, no murmurs
- **Respiratory:** Clear to auscultation
- **Catheter site:** Tunneled catheter in right IJ, no erythema, drainage, or tenderness
- **Skin:** No petechiae, no Janeway lesions or Osler nodes

### Workup and Results
| Test | Result | Reference Range |
|------|--------|-----------------|
| WBC | 18,500/mcL | 4,500-11,000/mcL |
| Blood cultures (2 sets) | Gram-positive cocci in clusters | Negative |
| Lactate | 2.8 mmol/L | 0.5-2.0 mmol/L |
| Procalcitonin | 8.5 ng/mL | <0.25 ng/mL |

**Culture identification (Day 2):** Methicillin-resistant *Staphylococcus aureus* (MRSA)
**Vancomycin MIC:** 1 mcg/mL

### Diagnosis
**MRSA catheter-related bloodstream infection** requiring vancomycin therapy with AUC-guided dosing

### Antimicrobial Pharmacology Principles Illustrated
1. **Vancomycin PK/PD:** AUC/MIC ratio of 400-600 is the target for optimal efficacy while minimizing nephrotoxicity.
2. **Renal dosing:** Vancomycin is primarily eliminated by the kidneys; in dialysis, dosing is based on dialysis schedule and post-dialysis redosing.
3. **Loading dose:** A loading dose of 25-30 mg/kg achieves therapeutic levels faster in serious infections.
4. **Therapeutic drug monitoring:** AUC-based monitoring is now preferred over trough-only monitoring.
5. **MIC importance:** Higher MIC values (>1 mcg/mL) may require alternative agents due to treatment failure risk.

### Treatment
1. **Vancomycin loading dose:** 2 g IV (25 mg/kg rounded)
2. **Maintenance dosing:** 1 g IV during last 1-2 hours of each dialysis session
3. **AUC monitoring:**
   - Obtain 2-point PK sampling (post-distribution peak and pre-dialysis trough)
   - Target AUC/MIC 400-600
4. **Catheter management:** Remove tunneled catheter if possible; if not, catheter lock therapy
5. **Transesophageal echocardiogram:** Rule out endocarditis in MRSA bacteremia
6. **Duration:** Minimum 4-6 weeks if endocarditis, 2-4 weeks if uncomplicated
7. **Repeat blood cultures** every 24-48 hours until negative

### Clinical Image

![MRSA SEM](case_01_image.jpg)

*Scanning electron micrograph of Methicillin-resistant Staphylococcus aureus (MRSA). MRSA carries the mecA gene encoding an altered penicillin-binding protein (PBP2a) with low affinity for beta-lactam antibiotics.*

**Image Source:** Centers for Disease Control and Prevention/Wikimedia Commons
**License:** Public Domain
**URL:** https://commons.wikimedia.org/wiki/File:MRSA_SEM_9994_lores.jpg

---

## Case 2: Aminoglycoside Nephrotoxicity and Ototoxicity

### Clinical Scenario
A 72-year-old male being treated for gram-negative sepsis develops rising creatinine and hearing loss while on gentamicin.

### Patient Demographics
- **Age:** 72 years
- **Sex:** Male
- **Weight:** 70 kg

### Chief Complaint
"I can't hear my wife talking" and decreased urine output

### History of Present Illness
The patient was admitted 12 days ago with *Pseudomonas aeruginosa* bacteremia from a urinary source. He was treated with piperacillin-tazobactam plus gentamicin 5 mg/kg/day (extended-interval dosing). Blood cultures cleared after 3 days, but the infectious disease consultant recommended completing 14 days of combination therapy. Over the past 3 days, his creatinine has risen from 1.2 to 2.8 mg/dL, and he has noticed difficulty hearing conversations.

### Physical Examination
- **Vital Signs:** BP 138/82 mmHg, HR 76 bpm, RR 16, T 37.0C
- **General:** Improved from admission, conversant
- **HEENT:** Hearing grossly diminished bilaterally; Weber lateralizes to neither side; Rinne: air > bone bilaterally
- **Cardiovascular:** Regular, no murmurs
- **Abdominal:** Soft, mild suprapubic tenderness
- **Neurological:** Mild unsteadiness on standing

### Workup and Results
| Test | Result | Reference Range |
|------|--------|-----------------|
| Creatinine (Day 1) | 1.0 mg/dL | 0.6-1.2 mg/dL |
| Creatinine (Day 8) | 1.2 mg/dL | - |
| Creatinine (Day 12) | 2.8 mg/dL | - |
| Gentamicin trough | 1.8 mcg/mL | <1 mcg/mL |
| BUN | 45 mg/dL | 7-20 mg/dL |
| Urinalysis | Granular casts, low-grade proteinuria | - |

**Audiometry:** Bilateral high-frequency sensorineural hearing loss (4000-8000 Hz)

### Diagnosis
**Aminoglycoside-induced nephrotoxicity and ototoxicity** - elevated trough indicates accumulation

### Antimicrobial Pharmacology Principles Illustrated
1. **Concentration-dependent killing:** Aminoglycosides are more effective at higher peak concentrations (Cmax/MIC ratio).
2. **Trough-related toxicity:** Nephrotoxicity and ototoxicity correlate with elevated trough levels and prolonged exposure.
3. **Renal accumulation:** Aminoglycosides accumulate in proximal tubular cells, causing acute tubular necrosis.
4. **Cochlear toxicity:** Destroys hair cells in the organ of Corti; irreversible.
5. **Extended-interval dosing rationale:** High peaks (efficacy) with drug-free intervals (reduced toxicity).
6. **Risk factors:** Age, baseline renal impairment, prolonged therapy, concurrent nephrotoxins.

### Treatment
1. **Discontinue gentamicin immediately**
2. **Continue piperacillin-tazobactam** alone to complete therapy if cultures remain negative
3. **Supportive care for AKI:**
   - IV fluids if not volume overloaded
   - Avoid additional nephrotoxins (NSAIDs, contrast, etc.)
   - Monitor for hyperkalemia
4. **Audiology follow-up:** Serial audiograms to document extent of hearing loss
5. **Vestibular assessment:** If symptoms of imbalance persist
6. **Patient education:** Hearing loss likely permanent; kidney function may recover

### Clinical Image

![Pseudomonas aeruginosa](case_02_image.jpg)

*Pseudomonas aeruginosa, a gram-negative bacterium that frequently requires aminoglycoside therapy, particularly for serious infections and in combination with beta-lactam antibiotics for synergy.*

**Image Source:** Wikimedia Commons
**License:** Public Domain
**URL:** https://commons.wikimedia.org/wiki/File:Pseudomonas_aeruginosa_01.jpg

---

## Case 3: Clostridioides difficile Infection Post-Antibiotic

### Clinical Scenario
A 68-year-old female develops profuse watery diarrhea 10 days after completing a course of clindamycin for a dental infection.

### Patient Demographics
- **Age:** 68 years
- **Sex:** Female
- **Weight:** 65 kg

### Chief Complaint
Watery diarrhea (10-15 episodes daily) with abdominal cramping for 3 days

### History of Present Illness
The patient completed a 7-day course of clindamycin for a dental abscess 10 days ago. Three days ago, she developed profuse, watery, foul-smelling diarrhea occurring 10-15 times per day. She has diffuse abdominal cramping, low-grade fever, and has noticed blood streaks in her stool today.

### Medications
- Lisinopril 10 mg daily
- Metformin 1000 mg twice daily
- Completed clindamycin 300 mg QID (7 days, ended 10 days ago)

### Physical Examination
- **Vital Signs:** BP 105/68 mmHg, HR 98 bpm, RR 18, T 38.3C
- **General:** Appears dehydrated, uncomfortable
- **Abdominal:** Diffuse tenderness, hyperactive bowel sounds, no rebound or guarding
- **Rectal:** Guaiac positive stool

### Workup and Results
| Test | Result | Reference Range |
|------|--------|-----------------|
| WBC | 22,400/mcL | 4,500-11,000/mcL |
| Creatinine | 1.6 mg/dL | 0.6-1.2 mg/dL |
| Albumin | 2.8 g/dL | 3.5-5.0 g/dL |
| Lactate | 1.8 mmol/L | 0.5-2.0 mmol/L |
| C. difficile toxin PCR | Positive | Negative |
| C. difficile toxin EIA | Positive | Negative |

**CT Abdomen:** Diffuse colonic wall thickening consistent with colitis

### Diagnosis
**Clostridioides difficile infection (CDI)** - moderate-severe (WBC >15,000, creatinine rise, hypoalbuminemia)

### Antimicrobial Pharmacology Principles Illustrated
1. **Disruption of normal flora:** Clindamycin has excellent anaerobic coverage that disrupts protective gut microbiome.
2. **C. difficile pathogenesis:** Spore-forming organism produces toxins A and B causing colonic inflammation.
3. **High-risk antibiotics:** Clindamycin, fluoroquinolones, cephalosporins, and carbapenems have highest CDI risk.
4. **Vancomycin oral formulation:** Achieves high colonic concentrations with minimal systemic absorption - treatment of choice.
5. **Fidaxomicin:** Narrow-spectrum macrolide that preserves gut flora; lower recurrence rates.
6. **Metronidazole role:** Now reserved only for non-severe CDI when oral vancomycin unavailable.

### Treatment
1. **Oral vancomycin 125 mg QID for 10-14 days** (first-line for moderate-severe CDI)
2. **IV fluids** for dehydration and acute kidney injury
3. **Avoid antidiarrheals** (loperamide) - can worsen toxin retention
4. **Contact isolation precautions**
5. **Monitor for complications:**
   - Fulminant colitis (ileus, toxic megacolon)
   - Perforation
   - If refractory: surgical consultation
6. **Consider fidaxomicin** for patients at high risk of recurrence
7. **Bezlotoxumab** (anti-toxin B antibody) for recurrent CDI prevention

### Severity Classification and Treatment

| Severity | Criteria | Treatment |
|----------|----------|-----------|
| Non-severe | WBC <15,000, Cr <1.5x baseline | PO vancomycin 125 mg QID or fidaxomicin |
| Severe | WBC >15,000 OR Cr >1.5x baseline | PO vancomycin 125 mg QID |
| Fulminant | Hypotension, shock, ileus, megacolon | PO vancomycin 500 mg QID + IV metronidazole + surgical consult |

### Key Learning Points
- C. difficile is the most common healthcare-associated infection
- Oral vancomycin (not IV) is the treatment - it is not absorbed systemically
- Antimicrobial stewardship reduces CDI incidence
- Recurrence occurs in 20-25% of cases; fecal microbiota transplant effective for multiply recurrent CDI